Ranbaxy whistleblower on the perils of a globalized supply chain, fraud enablers
This article was originally published in Scrip
Countries that supply medicines to the US should be "incentivized" to upgrade their skills, comply with American quality standards and improve public health for their own citizens. And those that are repeatedly not up to scratch should face punitive action. So says Ranbaxy whistleblower Dinesh Thakur.